Amedes Group signs DNA testing licensing agreement with Chronix Biomedical Inc.

CLICK HERE

CHRONIX BIOMEDICAL, INC

Chronix Biomedical, Inc.
is a molecular diagnostics company creating laboratory developed blood
tests, that are designed for therapy monitoring for patients with
chemotherapy or immunotherapy and for relapse monitoring after tumor
resection.

CNI MONITOR

CNI Monitor

Provides earliest determination of the efficacy of cancer therapies.

READ MORE

All Chronix tests are blood tests (Liquid biopsy tests) which detect tumor-derived cell-free DNA in blood samples of patients. Gains and losses of large chromosome sections that are present in the genome of cancer cells are detected and combined in a comprehensive copy number instability (CNI) score that can indicate tumor existance, remission or progression. Chronix blood tests are suitable for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection (CNI MONITOR).

WHY OUR TESTS ARE SO EFFECTIVE?

CHRONIX NEWS

Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO

Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

READ MORE

VIDEOS

WATCH MORE

EVENTS

VIEW MORE

ORDER TESTS

Go to Modern Cancer Diagnostics or Advanced Cancer Diagnostics to order our tests

DOCTORS ABOUT OUR TESTS

“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”
Howard Urnovitz, CEO of Chronix Biomedical
READ MORE